• November 3 - Shenzhen Salubris Pharmaceutical Co., Ltd. was incorporated.

  • Its first product Xindakang (Azithromycin Dispersible Tablets) was produced.

  • The pharmaceutical factory of Shenzhen Salubris Pharmaceutical Co., Ltd. was completed and started operation.

  • Xinlixin (Cefuroxime Sodium for Injection), the first powder injection product of Salubris, began production.

  • Taijia (Clopidogrel Bisulfate Tablets), an exclusive product of Salubris, began production and was listed in Shenzhen Municipal High-tech Program.

  • “Taijia” (Clopidogrel Bisulfate Tablets) and “Xinminting” (Desloratadine Tablets) were selected as 2002 national key new products.

  • In October - The bulk drug factory of Shenzhen Salubris Pharmaceutical Co., Ltd. was completed and started operation.

  • Salubris was selected as “Guangdong Provincial Innovative Enterprise in Pharmaceutical Industry over Thirty Years of the Reform and Opening-up Policy”.

  • Salubris R&D Center was recognized as a “Municipal Level R&D Center in Shenzhen (under the category of technology centers)”.

  • Salubris was evaluated to be a “Pharmaceutical Enterprise with AAA Credit Rating in Guangdong Province”.

  • Salubris was recognized as a “National High-tech Enterprise”

  • Salubris (Shandong) Production Base for Drug Intermediate and Bulk Drug was completed and started production.

  • Shenzhen Salubris Pharmaceutical Co., Ltd. was successfully listed in Shenzhen Stock Exchange.

  • Salubris worked with Shanghai Institute of Pharmaceutical Industry to build an associated research center.

  • Salubris won the award of “Top 500 Asian Brands”.

  • Salubris was recognized as a “Key High-tech Enterprise of China’s Torch Program”.

  • The Company worked with Tsinghua University to establish the “Tsinghua University - Salubris Associated R&D Center for Small Molecule Drugs”.

  • Salubris (Pingshan) Industrial Base for Biomedicine and Pharmaceutic Preparation was completed.

  • Salubris Technology Center was recognized as a “National Level Corporate Technology Center”.

  • Salubris (Daya Bay) Base for Oral Dosage and Chemical Raw Medicine was established.

  • Shenzhen Post-doctoral Innovative Practice Base (municipal level) was founded.

  • Allisartan Isoproxil Tablets (Xinlitan) was selected as “2013 Top 10 Significant Prescription Medicine”.

  • The production base of Genemen Biotech (Suzhou) Co., Ltd. joined Salubris.

  • The R&D base of Genekey Biotech (Chengdu) Co., Ltd. joined Salubris.

  • Salubris showed up in Times Square, New York.

  • Salubris acquired Shenzhen Keyidun Biomedical Technology Co., Ltd.

  • Taijia won the Gold Award for Chinese Patents.

  • Salubris worked with the National Key Laboratory of Biotherapy, Sichuan University, to launch strategic cooperation in innovative medicine.

  • Salubris acquired Alain Medical (Beijing) Co., Ltd.

  • Salubris (Huizhou) was recognized as a national high-tech enterprise.

  • Salubris was entitled to be China National Demonstration Enterprise in Technology Innovation.

  • Salubris solely funded the “Whole-hearted Care” program of whole-process management and free drugs for patients with acute coronary syndrome (ACS).

  • The production platform FlexFactory was completed in Suzhou Genemen Biotech (Suzhou) Co., Ltd.

  • The project of No. 507 APIworkshop in Daya Bay Plant was successfully completed and put into use.

  • Salubris Biotherapeutics, Inc. was incorporated in the United States.

  • Xinlitan (Allisartan Isoproxil Tablets) was listed in theNational Reimbursement List.